Sobi publishes report for the second quarter 2021
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the second quarter 2021. Total revenue amounted to SEK 3,211 M, 14 per cent growth at CER compared with the same period 2020. EBITA was SEK 922 M, resulting in an EBITA margin of 29 per cent. April – June · Total revenue of SEK 3,211 M (3 070), 5 per cent growth and 14 per cent at CER · EBITA[1] was SEK 922 M (1,018), with an EBITA margin[1] of 29 per cent (33) · Earnings per share (EPS) before dilution of SEK 0.91 (0.96) · Haematology sales were SEK 2,125 M (2,037), 12 per